Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abingworth Adds Stakes To Gilead’s Trodelvy Gamble

Executive Summary

The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.

You may also be interested in...



Dato-DXd Filing Lifts Mood For AstraZeneca Investors

AstraZeneca and Daiichi-Sankyo are targeting only non-squamous patients with their first Dato-DXd filing, but are still on course for a first-in-class approval by year end.

Do The Dark Clouds Over Gilead’s Trodelvy Have A Silver Lining?

Despite a primary endpoint miss in previously treated NSCLC in EVOKE-01, analysts say the drug still has points of differentiation from the competition. 

Corbus And Janux Lead Q1’s Small-Cap Winners

Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel